Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

American College of Cardiology Meeting In Brief: Merck's Mevacor

Executive Summary

Merck's Mevacor: In 1,351 patients having undergone CABG surgery with saphenous vein grafts, aggressive lipid-lowering therapy to below 100 mg/dL for LDL cholesterol resulted in a statistically significant 29% reduction in risk for substantial atherosclerosis progression in the saphenous vein graft compared to moderate lipid-lowering therapy to reduce LDL cholesterol to below 140 mg/dL, Lucien Campeau, MD, Montreal Heart Institute, reported March 26. The aggressive treatment group received an average 76 mg of lovastatin daily compared to an average daily dose of 4 mg in the moderate treatment group. A separate endpoint of the effect of low-dose anticoagulation therapy with warfarin showed no influence on atherosclerosis progression. Additionally, there was a trend for improvement in clinical outcomes in the aggressive lipid-lowering group over the mean 4.5 years of follow-up for the combined events of death, non-fatal myocardial infarction, stroke, angioplasty and bypass...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027935

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel